<DOC>
	<DOCNO>NCT02461953</DOCNO>
	<brief_summary>This study prospective , randomize , control multicenter clinical study . The aim study investigate whether combination maintenance hemodialysis ( MHD ) hemoperfusion ( HP ) could improve clearance rate middle large molecule uremic toxin improve quality life MHD patient reduce mortality rate .</brief_summary>
	<brief_title>Combination Hemodialysis With Hemoperfusion：A Clinical Study</brief_title>
	<detailed_description />
	<criteria>1 . Age≥18 , male female 2 . Maintenance hemodialysis duration＞3 month 3 . Regular hemodialysis,3 time week,4 hour per session 4 . Vascular access unlimited 5. iPTH≥300pg/ml 6 . Sign write informed consent 1 . Allergic dialysis equipment 2 . PLT＜60×10^9/L 3 . Blood flow＜200ml/min 4 . Serum albumin＜30g/L 5 . Kt/V＜1.2 6. iPTH＞800pg/ml 7 . Hemodiafiltration 8 . Coagulation disorder , severe bleeding tendency , active bleeding 9 . Severe hypotension , severe cardiopulmonary insufficiency 10 . Under drug trial 11 . Acute infection , severe heart , lung , liver , nervous disease , malignant tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>hemodialysis</keyword>
	<keyword>hemoperfusion</keyword>
	<keyword>quality life</keyword>
</DOC>